Decision-making factors in AML:

Insights from BSH 2022

Treatment selection and care for patients with AML can be challenging, so we spoke to three experts in the field about their practice and the factors they consider when making choices for, and with, their patients.

Question svg

Explore the questions and watch the videos below to find out what drives decision-making for Dr Victoria Campbell, Dr Steven Knapper and Dr Priyanka Mehta

The role of real-world
evidence in clinical
practice

Answer two quick questions and watch the video

Begin
Skip to Video

The role of real-world evidence in clinical practice

Question 1

What proportion of patients received an HSCT following treatment with Vyxeos Liposomal in the French real-world study?

Please select an answer




X Incorrect - 35%

Patients received an HSCT in each study at the following rates:

France RWE: 35%1

England RWE: 25%2

Germany RWE: 62%3

Italy RWE: 40% of those who achieved CR/CRi4

Correct - Thank you

Patients received an HSCT in each study at the following rates:

France RWE: 35%1

England RWE: 25%2

Germany RWE: 62%3

Italy RWE: 40% of those who achieved CR/CRi4

Question 2

Real-world studies complemented the mOS data for Vyxeos Liposomal from Study 301. What range do these results sit within?

Please select an answer



X Incorrect - 16 months - NR

France RWE: 16.1 months1

England RWE: 16.6 months2

Germany RWE: 21 months3

Italian RWE: mOS NR - 68.6% at 12 months4

Correct - Thank you

France RWE: 16.1 months1

England RWE: 16.6 months2

Germany RWE: 21 months3

Italian RWE: mOS NR - 68.6% at 12 months4

Back
Next
Skip to Video

The role of real-world evidence in clinical practice

Watch as AML experts Steven Knapper and Victoria Campbell discuss their key takeaways from the available studies.

Back

Selecting a treatment
approach: Intensive vs
non-intensive chemotherapy

Answer two quick questions and watch the video

Begin
Skip to Video

Selecting a treatment approach: Intensive vs non-intensive chemotherapy

Question 1

Based on the ASH 2020 guidelines, which is the suggested treatment for older adults with AML who are not eligible for HSCT?

Please select an answer



X Incorrect - Intensive anti-leukaemic therapy followed by post-remission therapy

Recommendation 1
Anti-leukaemic therapy over best supportive care5

Recommendation 2
Intensive anti-leukaemic therapy over less-intensive anti-leukaemic therapy5

Recommendation 3
Patients who achieve remission following at least one cycle of intensive anti-leukaemic therapy should receive allogeneic HSCT if elligible. ASH guidelines suggest ineligible patients should receive postremission therapy over no additional therapy5

Correct - Thank you

Recommendation 1
Anti-leukaemic therapy over best supportive care5

Recommendation 2
Intensive anti-leukaemic therapy over less-intensive anti-leukaemic therapy5

Recommendation 3
Patients who achieve remission following at least one cycle of intensive anti-leukaemic therapy should receive allogeneic HSCT if elligible. ASH guidelines suggest ineligible patients should receive postremission therapy over no additional therapy5

Question 2

Which clinical factors should be considered when selecting a treatment option for patients with AML-MRC/t-AML?

Please select an answer



X Incorrect - All of the above

ECOG PS, cytogenetic risk, comorbidities, and age are all among the factors to be considered in patient assessment and treatment selection7-9

Correct - Thank you

ECOG PS, cytogenetic risk, comorbidities, and age are all among the factors to be considered in patient assessment and treatment selection7-9

Back
Next
Skip to Video

Selecting your treatment approach: Intensive vs non-intensive chemotherapy

Experts share the factors that affect their choice to administer intensive or non-intensive chemotherapy to AML-MRC and t-AML patients.

Back

The value of supportive
care in IC: Managing
myelosuppression

Answer two quick questions and watch the video

Begin
Skip to Video

The value of supportive care in IC: Managing myelosuppression

Question 1

Based on the data from Study 301, how much longer does neutrophil and platelet recovery take for Vyxeos Liposomal patients vs those on DA 3+7?

Please select an answer




X Incorrect - 6-8 days

Median time to platelet and neutrophil recovery is 6-8 days longer with Vyxeos Liposomal vs DA 3+76

question3_infograph
Correct - Thank you

Median time to platelet and neutrophil recovery is 6-8 days longer with Vyxeos Liposomal vs DA 3+76

question3_infograph

Question 2

True or false: Prolonged myelosuppression with Vyxeos Liposomal vs DA 3+7 also translated into higher early mortality rates?

Please select an answer


X Incorrect - False

Day 30 and Day 60 mortality rates were lower with Vyxeos Liposomal vs DA 3+7:

France RWE: 30-day – 6%, 60-day – 8%1
England RWE: 30-day – 7%, 60-day – 15%2
Germany RWE: 30-day – 8%3
Italian RWE: 60-day – 7%4
Study 301: Vyxeos Liposomal 30-day - 6%, 60-day - 14% vs DA 3+7 30-day - 11%, 60-day 21%6

Correct - Thank you

Day 30 and Day 60 mortality rates were lower with Vyxeos Liposomal vs DA 3+7:

France RWE: 30-day – 6%, 60-day – 8%1
England RWE: 30-day – 7%, 60-day – 15%2
Germany RWE: 30-day – 8%3
Italian RWE: 60-day – 7%4
Study 301: Vyxeos Liposomal 30-day - 6%, 60-day - 14% vs DA 3+7 30-day - 11%, 60-day 21%6

Back
Next
Skip to Video

The value of supportive care in IC: Managing myelosuppression

Experts share their experience of treating patients with Vyxeos Liposomal as well as advice on how myelosuppression can be managed following IC.

Back

Championing patient care
by making the most of the
AML community

Answer two quick questions and watch the video

Begin
Skip to Video

Championing patient care by making the most of the AML community

Question 1

What type of support would you find most useful?

Please select an answer




Thank you

Question 2

What type of learning events do you prefer?

Please select an answer



Thank you
Back
Next
Skip to Video

Championing patient care by making the most of the AML community

Experts share their tips and advice on forging a successful AML treatment practice.

Back
Abbreviations

AML, acute myeloid leukaemia; AML-MRC, acute myeloid leukaemia with myelodysplasia-related changes; ASH, American Society of Hematology; BSH, British Society for Haematology; CR, complete response; CRi, complete response with incomplete platelet or neutrophil recovery; DA, daunorubicin + cytarabine; ECOG, Eastern Cooperative Oncology Group; HMA, hypomethylating agent; HSCT, haematopoietic stem cell transplantation; IC, intensive chemotherapy; IQR, interquartile range; LDAC, low-dose cytarabine; mOS, median overall survival; NR, not reached; PS, performance status; RWE, real-world evidence; t-AML, therapy-related AML

References
  1. Chiche E, et al. Blood Adv 2021;5(1):176–184
  2. Legg A, et al. Blood 2021; 138 (Suppl.1): 2310
  3. Rautenberg C, et al. Blood Cancer J 2021;11:164
  4. Guolo F, et al. Blood Cancer J 2020;10(10):96
  5. Sekeres M, et al. Blood Adv 2020;4(15):3528–3549
  6. Lancet JE, et al. J Clin Oncol 2018;36(26):2684–2692
  7. Wheatley K, et al. Br J Haematol 2009;145(5):598–605
  8. Deschler B, et al. Haematologica 2013;98(2):208–216
  9. Ferrara F, et al. Leukemia 2013;27(5):997–999

ADVERSE EVENTS REPORTING

Adverse events should be reported. For the UK, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

For the Republic of Ireland, reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue

Adverse events should also be reported to Jazz Pharmaceuticals by phone: +44 8081890387 (UK toll-free) or +353 1 968 1631 (Republic of Ireland).

UK-VYX-2200064 | June 2022